These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 20099349

  • 1. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A, Blakeborough A, Breuer J, Grazioli L, Gschwend S, Hammerstingl R, Heinz-Peer G, Kittner T, Laghi A, Leen E, Lencioni R, Lucidarme O, Remplik P, Robinson PJ, Ruehm SG, Schaefer F, Stoupis C, Tombach B, Valette PJ, Zech CJ, Huppertz A.
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ, Kim BS, Kim MJ, Kim SH, de Campos RO, Hernandes M, Semelka RC.
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [Abstract] [Full Text] [Related]

  • 3. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, Moeller A, Seeberg AH, Lodemann KP.
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G, Altmeyer K, Kirchin MA, Seidel R, Grazioli L, Morana G, Saini S.
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [Abstract] [Full Text] [Related]

  • 5. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV, Bourne MW, Sardanelli F, Wasser MN, Bonomo L, Boetes C, Müller-Schimpfle M, Hall-Craggs MA, Hamm B, Orlacchio A, Bartolozzi C, Kessler M, Fischer U, Schneider G, Oudkerk M, Teh WL, Gehl HB, Salerio I, Pirovano G, La Noce A, Kirchin MA, Spinazzi A.
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [Abstract] [Full Text] [Related]

  • 6. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU, Reiser MF, Huber AM.
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [Abstract] [Full Text] [Related]

  • 7. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S, Gupta RT, Boll DT, Merkle EM.
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [Abstract] [Full Text] [Related]

  • 8. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB.
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [Abstract] [Full Text] [Related]

  • 9. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, Han JK, Choi BI.
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [Abstract] [Full Text] [Related]

  • 10. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.
    Zizka J, Klzo L, Ferda J, Mrklovský M, Bukac J.
    Eur J Radiol; 2007 May; 62(2):186-91. PubMed ID: 17367974
    [Abstract] [Full Text] [Related]

  • 11. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M, Picone D, Cabibbo G, Midiri M, Lagalla R, Brancatelli G.
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM, Ouyang H, Zhou CW.
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [Abstract] [Full Text] [Related]

  • 13. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L, Morana G, Kirchin MA, Schneider G.
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
    Hammerstingl R, Adam G, Ayuso JR, Van Beers B, Belfiore G, Bellin MF, Bongartz G, Ernst O, Frericks B, Giuseppetti G, Heinz-Peer G, Laghi A, Martin J, Pering C, Reimer P, Richter GM, Roemer FW, Schäfer FK, Vilgrain V, Vogl TJ, Weishaupt D, Wall A, Zech CJ, Tombach B.
    Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
    [Abstract] [Full Text] [Related]

  • 15. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM.
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [Abstract] [Full Text] [Related]

  • 16. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI.
    Lee MS, Lee JY, Kim SH, Park HS, Kim SH, Lee JM, Han JK, Choi BI.
    J Magn Reson Imaging; 2011 Jan; 33(1):149-59. PubMed ID: 21182133
    [Abstract] [Full Text] [Related]

  • 17. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C, Vernuccio F, Rini F, Duca P, Tuscano B, Brancatelli G, Vanzulli A.
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [Abstract] [Full Text] [Related]

  • 18. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver.
    Chung SH, Kim MJ, Choi JY, Hong HS.
    J Magn Reson Imaging; 2010 Feb; 31(2):365-72. PubMed ID: 20099350
    [Abstract] [Full Text] [Related]

  • 19. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC, Inan N, Anik Y, Erturk MS, Ural D, Demirci A.
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [Abstract] [Full Text] [Related]

  • 20. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).
    Martincich L, Faivre-Pierret M, Zechmann CM, Corcione S, van den Bosch HC, Peng WJ, Petrillo A, Siegmann KC, Heverhagen JT, Panizza P, Gehl HB, Diekmann F, Pediconi F, Ma L, Gilbert FJ, Sardanelli F, Belli P, Salvatore M, Kreitner KF, Weiss CM, Zuiani C.
    Radiology; 2011 Feb; 258(2):396-408. PubMed ID: 21163915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.